Last updated: 7 July 2020 at 5:42pm EST

Investments Ab Karolinska D... Net Worth




The estimated Net Worth of Investments Ab Karolinska D... is at least $21.3 Million dollars as of 7 July 2020. Investments D owns over 241,703 units of Aprea Therapeutics stock worth over $6,416,127 and over the last 5 years Investments sold APRE stock worth over $14,930,464.

Investments D APRE stock SEC Form 4 insiders trading

Investments has made over 2 trades of the Aprea Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Investments sold 241,703 units of APRE stock worth $8,350,839 on 7 July 2020.

The largest trade Investments's ever made was selling 241,703 units of Aprea Therapeutics stock on 7 July 2020 worth over $8,350,839. On average, Investments trades about 150,750 units every 28 days since 2019. As of 7 July 2020 Investments still owns at least 1,992,586 units of Aprea Therapeutics stock.

You can see the complete history of Investments D stock trades at the bottom of the page.



Insiders trading at Aprea Therapeutics

Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant..., and John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.



What does Aprea Therapeutics do?

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.



Complete history of Investments D stock trades at Aprea Therapeutics

Insider
Trans.
Transaction
Total value
Investments Ab Karolinska D...
Sale $8,350,839
7 Jul 2020
Investments Ab Karolinska D...
Sale $6,579,625
13 Apr 2020


Aprea Therapeutics executives and stock owners

Aprea Therapeutics executives and other stock owners filed with the SEC include: